Anavex Life Sciences

Historical price data

Anavex Life Sciences is a clinical-stage biotech focused on developing oral therapeutics for central nervous system (CNS) disorders by targeting the sigma-1 receptor (SIGMAR1). Its lead asset, blarcamesine, has generated pivotal clinical data in Alzheimer's disease and holds Orphan Drug Designation for Rett syndrome, positioning it in multi-billion dollar markets with high unmet need. The company operates with a lean, virtual model, advancing a precision medicine platform that aims to modify disease pathology rather than just alleviate symptoms.

The SIGMACEPTOR™ Discovery Platform focuses on developing small molecule agonists that activate the sigma-1 receptor (SIGMAR1), a chaperone protein at the mitochondrion-associated ER membrane, to restore cellular homeostasis, enhance autophagy, and provide neuroprotection.